Photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes to promote PD-L1 multivalent binding for effective immune checkpoint blockade therapy
Acta Pharmaceutica Sinica B · 2024-03 · 14 (3) · 1428-1440
DOI: 10.1016/j.apsb.2023.09.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2024-03. Verfasst von Youngjoo Lee und 9 weiteren Autor:innen. Beteiligte Einrichtung: KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul 02841, Republic of Korea. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Science, ICT and Future Planning, Korea Institute of Science and Technology.
Abstract (Originalsprache)
Immune checkpoint blockade (ICB) therapy targeting PD-L1 via monoclonal antibody (mAb) has shown extensive clinical benefits in the diverse types of advanced malignancies. However, most patients are completely refractory to ICB therapy owing to the PD-L1 recycling mechanism. Herein, we propose photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes (immune checkpoint blockade liposomes; ICB-LPs) to promote PD-L1 multivalent binding for inducing lysosomal degradation of PD-L1 in tumor cells. The ICB-LPs are prepared by formulation of DC8,9PC with photo-polymerized diacetylenic moiety, 1,2-dipalmitoylphosphatidylcholine (DPPC) and anti-PD-L1 peptide (D-form NYSKPTDRQYHF)-conjugated DSPE-PEG2k (anti-PD-L1-DSPE-PEG2k) in a molar ratio of 45:45:10, followed by cross-linking of liposomal bilayer upon UV irradiation. The 10 mol% anti-PD-L1-DSPE-PEG2k incorporated ICB-LPs have a nano-sized lipid bilayer structure with an average diameter of 137.7 ± 1.04 nm, showing a high stability in serum condition. Importantly, the ICB-LPs efficiently promote the multivalent binding with PD-L1 on the tumor cell membrane, which are endocytosed with aim to deliver PD-L1 to the lysosomes, wherein the durable PD-L1 degradation is observed for 72 h, in contrast to anti PD-L1 mAbs showing the rapid PD-L1 recycling within 9 h. The in vitro co-culture experiments with CD8+ T cells show that ICB-LPs effectively enhance the T cell-mediated antitumor immune responses against tumor cells by blocking the PD-L1/PD-1 axis. When ICB-LPs are intravenously injected into colon tumor-bearing mice, they efficiently accumulate within the targeted tumor tissues via both passive and active tumor targeting, inducing a potent T cell-mediated antitumor immune response by effective and durable PD-L1 degradation. Collectively, this study demonstrates the superior antitumor efficacy of crosslinked and anti-PD-L1 peptide incorporated liposome formulation that promotes PD-L1 multivalent binding for trafficking of PD-L1 toward the lysosomes instead of the recycling endosomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul 02841, Republic of Korea.
- Medicinal Materials Research Center, Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea.
- College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea.
- Department of Bioengineering, Korea University, Seoul 02841, Republic of Korea.
Förderung
- National Research Foundation of Korea
- Ministry of Science, ICT and Future Planning
- Korea Institute of Science and Technology
Zitieren
APA
Lee, Y., Song, S., Yang, S., Kim, J., Moon, Y., Shim, N., Yoon, H. Y., Kim, S., Shim, M. K., & Kim, K. (2024). Photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes to promote PD-L1 multivalent binding for effective immune checkpoint blockade therapy. Acta Pharmaceutica Sinica B, 14(3), 1428-1440. https://doi.org/10.1016/j.apsb.2023.09.007
Vancouver
Lee Y, Song S, Yang S, Kim J, Moon Y, Shim N, et al. Photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes to promote PD-L1 multivalent binding for effective immune checkpoint blockade therapy. Acta Pharmaceutica Sinica B. 2024;14(3):1428-1440. doi:10.1016/j.apsb.2023.09.007
BibTeX
@article{Lee2024,
author = {Lee, Youngjoo and Song, Sukyung and Yang, Suah and Kim, Jinseong and Moon, Yujeong and Shim, Nayeon and Yoon, Hong Yeol and Kim, Sehoon and Shim, Man Kyu and Kim, Kwangmeyung},
title = {Photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes to promote PD-L1 multivalent binding for effective immune checkpoint blockade therapy},
journal = {Acta Pharmaceutica Sinica B},
year = {2024},
volume = {14},
number = {3},
pages = {1428--1440},
doi = {10.1016/j.apsb.2023.09.007}
}
EUVIMED